Ask AI
ProCE Banner Activity

Unmasking EGPA: Expert Strategies for Delivering Guideline-Concordant Care

Clinical Thought

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis. In this commentary, experts answer key learner questions on how to provide guideline-concordant care when confirming an EGPA diagnosis and using immunosuppressive agents like glucocorticoids and rituximab in EGPA treatment.

Released: November 05, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Praveen Akuthota, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Connect Biopharma, Envada Biosciences, GlaxoSmithKline, Sanofi, Vida Ventures.

Michael E. Wechsler, MD, MMSc: consultant/advisor/speaker: Allakos, Amgen, Areteia, Arrowhead, AstraZeneca, Avalo, Belenos Bio, Celldex, Connect Biopharma, GlaxoSmithKline, Enveda, Equillium, General Medicines, Jasper, Kinaset, Kymera, Lilly, Merck, myBiometry, Pharming, Phylaxis, Pulmatrix, Rapt, Recludix Pharma, Regeneron, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Teherex, Uniquity Bio, Verona Pharma, Zurabio; researcher: Amgen, AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi/Genzyme, Upstream Bio; individual publicly traded stock/stock options: Upstream Bio.